BACK
TO MAIN
PAGE

Glioblastoma (CMV-positive) 

General Information

Glioblastoma (GBM) is a fast-growing and aggressive brain tumour that can result in death in six months or less, if untreated.

Median age of diagnosis is 64 years and it is more common in men as compared to women

GBMs present unique treatment challenges due to the localisation of tumours in the brain, inherent resistance to conventional therapy, limited capacity of the brain to repair itself, migration of malignant cells into adjacent brain tissue and the variably disrupted tumour blood supply, which inhibits effective drug delivery.

Show More

Epidemiology

Survival is poor with approximately 40% survival in the first year post diagnosis and 17% in the second year.​

GBM has an incidence of 3.21 per 100,000 population.

Vaccines
Pipeline

1
Vaccines in
the pipeline

Technology Platforms

  • Virus-like particle​ (1)

DEVELOPMENT PHASES

  • Phase II (1)

TRIAL POPULATION

    Adults + Older Adults (1)

Source: 
https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme
[Accessed: November 2022]

Vaccines Europe Pipeline Review

Download our pipeline review